Dogecoin eyes new ATH at $1.40 as rival token targets 18,540% growth

0
4

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Dogecoin is poised for a new ATH at $1.40, while Rexas Finance competes with a 18,540% potential surge.

Dogecoin is set to skyrocket to an all-time high (ATH) of $1.40 based on the current analysis and is currently trading at $0.32322 with a gain of 4% in the last 24 hours. As one of the competing tokens capturing investors, Dogecoin’s attention is set to surge by 18540%. The Dogecoin competitor is Rexas Finance (RXS). 

This token focuses on real-world assets (RWA) and is currently in presale stage 10, where it has been making headlines with its presale moving fast and attracting many investors. It has raised over $31 million in a few weeks, while other projects take years.

Dogecoin primed for a massive surge: Could $1.40 be the next stop?

Over the past year, Dogecoin has experienced a roller coaster journey, increasing by nearly 250 percent before dropping dramatically. The token bounced back approximately 30% from a low of around $0.26, indicating its strength in the ever-changing crypto landscape. Several factors have been mentioned for this recovery: increased adoption and community support. According to the technical analysis, Dogecoin has passed the Fibonacci retracement level of 0.618 and is now ready for more growth.

The channel’s breakout is ongoing, and it is regarded as a strong support level around $0.26, where many traders see it as an entry point. Dogecoin is still gaining momentum, and analysts are confident it will hit new ATHs soon. Even some forecasts hypothesize that if this bullish growth continues, Dogecoin could increase to approximately $1.40, a paradigm shift for the token and its community.

Rexas Finance nears $33M presale target: Early investors eye massive gains

RXS, currently in Stage 10 of its presale, is selling for $0.150 and is expected to rise to $0.175 at the next stage. That’s a potential staggering increase for early investors.

Rexas Finance has already raised over $31 million of its target $33 million and sold close to 372 million tokens out of the 380 million available, with listings on platforms such as CoinMarketCap and CoinGecko. The project has also undergone extensive auditing by Certik to ensure transparency and security for investors. With RXS’s focus on real-world assets and strong presale performance, it becomes a very alluring project to bet upon.

https://twitter.com/rexasfinance/status/1857692542290059502

Rexas Finance: Could this be your 18,540% ROI opportunity?

Predictably, excitement about Rexas Finance is high, especially as the consensus is for some mind-blowing price prediction of up to 18,540%. The growing excitement around RWAs in the cryptocurrency space drives this projection for the token based on its distinct value proposition. With its increasing intersection with traditional finance, blockchain technology will benefit from projects such as Rexas Finance. Considering this, investors are keenly waiting to see how RXS will perform post-presale and whether it can keep up the momentum once it is in exchanges. At the current presale price of $0.150, there is an excellent opportunity for those who want to ride the growth wave.

Conclusion

Based on the current analysis, Dogecoin is poised for a $1.40  all-time high (ATH). Still, a Dogecoin competitor token that Rexas Finance deals with focuses on real-world assets (RWA)  based on its current momentum, where it is completing its presale stages before its schedule. It is poised for a whopping 18540% increase. Turning a few low investments amounts to thousands of dollars. With the next presale stage priced at $ 0.175, savvy investors are advised to visit Rexas Finance’s website and buy into the presale before it skyrockets to the next stage.

To learn more about RXS, visit the official website, Whitepaper, Twitter and Telegram.

Disclosure: This content is provided by a third party. crypto.news does not endorse any product mentioned on this page. Users must do their own research before taking any actions related to the company.


Credit: Source link

ads

RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here